

Time of disclosure: 19/03/2025
 Company: Vifor Pharma Group
 Disclosure Period: 01.01.2025 to 31.12.2025
 Currency: CZK

	Full Name <i>(Art. 1.01)</i>	HCPs: City of Principal Practice HCOs: city where registered <i>(Art. 3)</i>	Country of Principal Practice <i>(Schedule 1)</i>	Principal Practice Address <i>(Art. 3)</i>	Unique country identifier OPTIONAL <i>(Art. 3)</i>	Donations and Grants to HCOs <i>(Art. 3.01.1.a)</i>	Contribution to costs of Events <i>(Art. 3.01.1.b & 3.01.2.a)</i>			Fee for service and consultancy <i>(Art. 3.01.1.c & 3.01.2.c)</i>		TOTAL OPTIONAL
							Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event	Registration Fees	Travel & Accommodation	Fees	Related expenses agreed in the fee for service or consultancy contract, including travel & accommodation relevant to the contract	
HCPs	<i>INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up; itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)</i>											
	Ladislav Šenolt	Loděnice	Czech Republic	K Hůrce 427, 26712						26'538.02		26'538.02
	Martina Doubkova	Brno	Czech Republic	Jihlavská 20, 625 00						21'110.09		21'110.09
	Pavel Horák	Olomouc	Czech Republic	Panská 175/4, 779 00						26'654.37		26'654.37
	Zdenka Hruskova	Ricany	Czech Republic	Šumna 1733/3, 25101						23'354.30		23'354.30
	Vladimír Tesar	Praha 2	Czech Republic	U nemocnice 2, 128 08						37'911.46	29'500.00	67'411.46
	<i>OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons</i>											
	Aggregate amount attributable to transfers of value to such Recipients - <i>Art. 3.02</i>						N/A	N/A				
	Number of Recipients in aggregate disclosure - <i>Art. 3.02</i>						N/A	N/A				
	% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - <i>Art. 3.02</i>						N/A	N/A				
HCOs	<i>INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up; itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)</i>											
	<i>OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons</i>											
	Aggregate amount attributable to transfers of value to such Recipients - <i>Art. 3.02</i>											
	Number of Recipients in aggregate disclosure - <i>Art. 3.02</i>											
	% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - <i>Art. 3.02</i>											N/A
R & D	<i>AGGREGATE DISCLOSURE</i>											
	Transfers of Value re Research & Development as defined - <i>Article 3.04 and Schedule 1</i>											165'068.24